Insulin Glargine
Metabolic / DiabetesAlso known as: Lantus, Basaglar, Toujeo, Semglee
Mechanism
The most widely prescribed long-acting (basal) insulin in the world. Engineered to release slowly and steadily over 24+ hours with no sharp peak — mimicking the background insulin your pancreas normally drips out all day. You inject it once daily and it forms tiny clumps under the skin that dissolve gradually, providing a flat, predictable insulin level.
Technical detail
Long-acting recombinant insulin analog produced in E. coli. Two structural modifications: (1) Asn-A21 → Gly substitution (stabilizes molecule at acidic pH, prevents deamidation), (2) addition of two Arg residues at C-terminus of B-chain (B31-Arg, B32-Arg), shifting isoelectric point from pH 5.4 to ~6.7. Formulated at pH 4.0 (clear solution). Upon SC injection into physiological pH 7.4 environment, glargine precipitates into amorphous microprecipitates due to reduced solubility at neutral pH. Slow dissolution from depot → protracted absorption over 24+ hours. Metabolized to active metabolites M1 (21A-Gly-insulin, primary) and M2 (21A-Gly-des-30B-Thr-insulin). PK: onset 1-2 hours, no pronounced peak, duration 24-30 hours. Toujeo (U-300, 300 units/mL) has smaller depot surface area → even more prolonged absorption (>36 hours). IGF-1R affinity of parent molecule is ~6x human insulin, but metabolite M1 (predominant circulating form) has IGF-1R affinity similar to native insulin.
Effects
METABOLIC SYSTEM: Insulin glargine is a long-acting basal insulin analog designed to provide approximately 24-hour glucose-lowering activity from a single daily injection [pharmacological, RCT]. STRUCTURAL MODIFICATION: Two changes from native human insulin — (1) asparagine at A21 is replaced with glycine (prevents acid-catalyzed deamidation), and (2) two arginines are added to the C-terminus of the B-chain (shifts the isoelectric point from pH 5.4 to 6.7, rendering glargine soluble at acidic pH 4.0 but insoluble at physiological pH 7.4) [crystallographic, pharmacokinetic]. MICROPRECIPITATE DEPOT MECHANISM: Glargine is formulated as a clear acidic solution (pH 4.0). Upon subcutaneous injection, the pH neutralizes to 7.4, causing glargine to precipitate as amorphous microprecipitates in the subcutaneous tissue. These microprecipitates slowly dissolve, releasing glargine monomers and dimers for absorption [pharmacokinetic — Owens et al., 2000]. PHARMACOKINETICS (U-100 LANTUS): Onset: 1-2 hours. No pronounced peak (relatively peakless profile, though a slight peak at 8-12 hours exists in some patients). Duration: approximately 20-24 hours (some patients experience waning at 20-22 hours, necessitating evening dosing or consideration of longer-acting alternatives). TOUJEO (U-300): Three times the concentration of Lantus (300 units/mL vs. 100 units/mL). The higher concentration results in a smaller subcutaneous depot with reduced surface area-to-volume ratio → slower dissolution → flatter, more prolonged PK profile [pharmacokinetic — Becker et al., 2015]. Duration extends to approximately 30-36 hours. Lower intra-day glucose variability than U-100. Lower nocturnal hypoglycemia than U-100 (approximately 25-30% reduction) [RCT — EDITION trials]. Note: patients typically require 10-15% higher unit doses when switching from U-100 to U-300 (because the slower absorption results in lower bioavailability per unit). GLYCEMIC CONTROL: HbA1c reduction comparable to NPH insulin with significantly less nocturnal hypoglycemia — this established glargine as the basal insulin standard [RCT — landmark Riddle et al., 2003]. CARDIOVASCULAR: ORIGIN trial (2012, Gerstein et al.) — landmark CVOT: glargine U-100 vs. standard care in patients with pre-diabetes/early T2D. Neutral effect on MACE (no increased cardiovascular risk). No increased cancer risk (addressed a long-standing concern about insulin glargine and IGF-1 receptor affinity) [RCT — ORIGIN]. BIOSIMILARS: Multiple biosimilar glargines now available (Basaglar/Abasaglar — Lilly; Semglee — Mylan/Viatris; Rezvoglar — Lilly) — significantly improving cost access.
Practitioner Guide
ADMINISTRATION: Subcutaneous injection once daily (U-100 and U-300). U-100 (Lantus): typically injected at bedtime or in the morning — choose consistent timing. Bedtime dosing targets fasting glucose. Morning dosing may be preferred for patients with dawn phenomenon or those who prefer AM routine. U-300 (Toujeo): same flexibility, once daily at any consistent time. Inject in thigh, abdomen, or upper arm. Rotate within region. DOSING — TREAT-TO-TARGET APPROACH: This is the standard evidence-based titration method. Start: 10 units once daily (or 0.1-0.2 units/kg) in T2D. Titrate: increase by 2-4 units every 3-7 days, guided by fasting blood glucose. Target fasting glucose: 80-130 mg/dL (ADA), or individualized (less aggressive targets for elderly or hypoglycemia-prone patients: 100-150 mg/dL). Continue titrating until target achieved or hypoglycemia occurs. Average maintenance dose in T2D: 40-60 units/day (wide range: 20-100+ units). SWITCHING FROM NPH: Unit-for-unit conversion. If on twice-daily NPH: reduce total by 20% and give as once-daily glargine. Monitor fasting glucose and titrate. SWITCHING U-100 TO U-300: Same unit dose as starting point, but expect to increase by 10-15% over 2-4 weeks. Do NOT switch units — the SoloStar pen for Toujeo is calibrated in units, not mL. SWITCHING TO/FROM DEGLUDEC: Approximately unit-for-unit. Monitor closely for 2 weeks. BIOSIMILAR CONSIDERATIONS: Biosimilar glargines (Basaglar, Semglee, Rezvoglar) are therapeutically equivalent to Lantus. Switching is appropriate for cost savings — no dose adjustment needed, though monitoring during transition is prudent. Semglee is the first interchangeable biosimilar insulin (can be substituted at pharmacy level without prescriber authorization in many states). INJECTION TECHNIQUE: Use 4-5 mm pen needles. Do not mix glargine with other insulins (the acidic pH destabilizes other insulin analogs). Prime pen with 2 units before each injection. Hold needle in skin for 10 seconds after injection to prevent leakage. COST: Lantus: ~$300-400/month. Toujeo: ~$350-450/month. Biosimilars: ~$150-250/month (significant savings). Walmart ReliOn insulin (NPH) remains the cheapest option (~$25/vial) but with inferior PK profile. STORAGE: Unopened: refrigerate (2-8°C). In-use: room temperature for 28 days (U-100 and U-300). Do not freeze. COMBINATION WITH GLP-1 AGONIST: Soliqua (glargine U-100 + lixisenatide) available as a fixed-ratio combination — simplifies basal insulin + GLP-1 agonist therapy similar to Xultophy (degludec + liraglutide).
Research Summary
TIER 1: Riddle et al., 2003 — landmark treat-to-target RCT: glargine vs. NPH in T2D, equivalent HbA1c reduction with significantly less nocturnal hypoglycemia (establishing glargine as the modern basal insulin standard). EDITION trials (1-4): glargine U-300 vs. U-100, demonstrating equivalent HbA1c control with 25-30% less nocturnal hypoglycemia across T1D and T2D populations. ORIGIN trial (2012, Gerstein et al. — NEJM): 12,537 patients with pre-diabetes/early T2D, glargine neutral on MACE and cancer — landmark cardiovascular and cancer safety data. BRIGHT trial: glargine U-300 vs. degludec U-100 — similar glycemic control and hypoglycemia (first head-to-head of the two ultra-long basals). FDA-approved: Lantus (2000), Toujeo (2015). Biosimilar approvals: Basaglar (2015), Semglee (2020, interchangeable 2021), Rezvoglar (2021). TIER 2: Meta-analyses confirming glargine superiority to NPH for hypoglycemia (multiple Cochrane reviews). Systematic reviews of U-300 vs. U-100 outcomes. Cost-effectiveness analyses (biosimilars dramatically improve value proposition). Pharmacokinetic modeling of the microprecipitate depot mechanism (Owens et al., 2000). IGF-1 receptor binding studies addressing the cancer concern (glargine has slightly higher IGF-1R affinity than native insulin in vitro, but metabolite M1 has reduced affinity — ORIGIN trial settled the clinical question). TIER 3: Massive real-world evidence from diabetes registries worldwide (Lantus is the most-prescribed insulin globally). Primary care prescribing data. Patient satisfaction surveys. Pediatric endocrinology data (approved age ≥6 for T1D). Insulin access and affordability advocacy data. KEY FINDINGS: Insulin glargine is the most consequential basal insulin innovation — it replaced NPH as the standard and enabled modern treat-to-target titration protocols. The microprecipitate mechanism was pharmacologically elegant for its time. U-300 (Toujeo) offers a clinically meaningful PK improvement. ORIGIN provided critical long-term safety reassurance. Biosimilar availability is transforming access and affordability. GAPS: Long-term CVOT for U-300 specifically (ORIGIN used U-100). Real-world comparative effectiveness of biosimilar vs. originator beyond equivalence assumptions. Optimal basal insulin in the era of GLP-1 dominance (many T2D patients may not need basal insulin if started on GLP-1 agonists earlier). ACTIVE TRIALS: Ongoing real-world evidence studies. Biosimilar interchangeability studies. Combination therapy optimization.